Parameswaran Hari
Chief Development Officer Obsidian Therapeutics
Seminars
Thursday 19th November 2026
Advancing First-in-Class TIL Programs Through Uncertain Regulatory & Quality Expectations for Successful Approvals
1:45 pm
- Navigating first time interactions with inexperienced review teams
- Defining and defending potency assays for complex cell products
- Applying quality by design concepts to highly variable therapies
